Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tesaro Begins Dose-Finding Study | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Tesaro Begins Dose-Finding Study

Test rolapitant doses for CINV

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Tesaro, Inc. has initiated an open label, dose-finding and escalation study to evaluate the pharmacokinetics, safety and tolerability of an intravenous (IV) formulation of rolapitant in healthy volunteers. Rolapitant is an investigational neurokinin-1 (NK-1) receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting (CINV). Data from this Phase I study will be used to select the intravenous dose that will be advanced into a subsequent clinical study.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics